Sbfi26

Reagents: ferrostatin‐1 (CAS:347174–05‐4) and erastin (CAS:571203–78‐6) were all purchased from MedChemExpress (shanghai; China). SBFI26 (CAS:1541207–06‐0) was purchased from GLPBIO Technology (American). Antibodies: Primary antibodies were used as following: anti‐β‐actin antibody (1:1000, mAbcam 8226, Abcam), anti‐ALOX5 (1:500–1:1000, R1512‐14, HuaBio), anti‐ALOX12 (1:2000, AP8877B Abcepta Biotech), anti‐NFE2L2 (1:1000–1:2000, R1312‐8, HuaBio), anti‐GPX4 (1:500–1:2000, ET1706‐45, HuaBio), anti‐HO‐1 (1:1000, ET1604‐45, HuaBio), anti‐ATF4 (1:500–1:2000, ET1612‐37, HuaBio), secondary antibody was purchased from Beyotime (Shanghai, China).

MCF-7 cells and MCF-7/ADR cells were purchased from Nanjing KeyGen. Cells were maintained in RPMI-1640 media supplemented with 10% fetal bovine serum (ExCell Bio, Uruguay) and 1% penicillin/streptomycin at 37°C in a humidified 5% CO₂ atmosphere. MCF-7/ADR cells were cultivated in the presence of a low dose of doxorubicin hydrochloride (1 μg/mL, MCE, China) and passaged once in drug-free media before the tests to retain their resistance characteristic (Wang et al., 2016 (link)). MCF-7/ADR cells were transfected with FABP5-specific siRNA (sc-41237, Santa Cruz Biotechnology, USA) and control siRNA with 100 nM lipofectamine 3,000 reagents (L3000008, Invitrogen, USA) according to the instructions provided by the manufacturer. SBFI-26 (GC39236, GlpBio, USA), a FABP5 specific inhibitor, is used to suppress FABP5 expression. In 6 well plates, the cells were grown for observation. FABP5 expression was evaluated by qRT–PCR and WB technique 96 h after the transfection of cells (Lewuillon et al., 2022 (link)).